Senti Biosciences Holdings, Inc. (SNTI) stock
SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.23+0.00 (+0.84%)
Close on Oct 19, 2026Market cap $7.06MP/E –Yield –
Senti Biosciences net income
Net income is the profit left for shareholders after every expense, interest and tax.
Senti Biosciences's net income for the twelve months ending Jun 30, 2026 was -$49.56M. For fiscal 2025 it was -$61.44M. The highest annual figure on record is -$52.79M in fiscal 2024.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$61.44M | – |
| FY2024 | Dec 31, 2024 | -$52.79M | – |
| FY2023 | Dec 31, 2023 | -$71.06M | – |
| FY2022 | Dec 31, 2022 | -$58.21M | – |
| FY2021 | Dec 31, 2021 | -$55.32M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.75M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.13M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$610.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.87M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.11M | – |
| Q4 FY2023 | Dec 31, 2023 | -$71.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.72M | – |
| Q4 FY2022 | Dec 31, 2022 | -$58.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.64M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.55M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.90M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.41M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.00M | – |
See a number that looks wrong?